About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Lawyers Pursue Skin Cancer Cases After Medication Use

By: NewsUSA

(NewsUSA) - The anti-inflammatory medication dupilumab, marketed as Dupixent, is the subject of a lawsuit alleging a link between the use of the medication and the development of a type of skin cancer known as cutaneous T-cell lymphoma (CTCL).

Dupixent is prescribed for several medical conditions including asthma and eczema. CTCL is a type of skin cancer that develops in white blood cells, which help the body fight infection.

Early signs and symptoms of CTCL include red, scaly patches, rashes, lumps and bumps, discoloration, thickened skin, swollen lymph nodes, hair loss, itching, fever and chills, unexplained weight loss, pain or tenderness, and night sweats. As CTCL progresses, the visual changes can affect up to 80% of the skin’s surface. Ultimately, the disease can spread to internal organs, including the spleen and liver.

Dupixent manufacturers Regeneron Pharmaceuticals and Sanofi Genzyme failed to adequately warn of the risks in taking the drug, according to Ellen Relkin, partner in the law firm of Weitz & Luxenberg and practice group chair of the firm’s Drug and Medical Device Litigation team. The law firm of Weitz & Luxenberg is taking legal cases for patients who have and used an anti-inflammatory medication and have been diagnosed with skin cancer.

“Cutaneous T-cell lymphoma is a very rare type of skin cancer. This makes it all the more critical for the manufacturer to warn patients about the danger,” states Relkin.

A study in the Journal of the American Academy of Dermatology reported an increased risk of CTCL was found in a cohort of atopic dermatitis patients who used dupilumab. “The increased risk persisted after exclusion of prior disease-modifying antirheumatic drug use. Risk was not increased for other cutaneous or lymphoid malignancies,” the researchers wrote.

“Doctors and patients alike need to be sufficiently warned, and patients who take Dupixent, and their doctors, need to keep a careful eye out for any disturbing changes to their skin,” says Ms. Relkin.  

“Those who took Dupixent and are suffering deserve compensation. And we are going to help you get it,” she insists.

Weitz & Luxenberg is encouraging anyone diagnosed with CTCL who used Dupixent to contact the firm for information about legal options and a free initial consultation. Call (917) LAWYERS or visit https://www.weitzlux.com/firm-news/dupixent-skin-cancer-lawsuit-ctcl/.

 

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.